TABLE 2.
Comparison of PANSS Total Scores Between Perphenazine and Three SGAs With 95% CIs of Differences in LS Meansa
| Treatment | LS Mean of PANSS Total Score |
Difference from Perphenazine |
SD of Difference in LS Mean |
95% CI of Group Differences: Lower Limit |
95% CI of Group Differences: Upper Limit |
pb |
|---|---|---|---|---|---|---|
| ITT analysis | ||||||
| All data during 18 mos (n = 5852 observations from 1047 patients) | ||||||
| Perphenazine | 67.72 | |||||
| Olanzapine | 65.93 | 1.79 | 0.74 | −0.04 | 3.54 | |
| Quetiapine | 68.02 | −0.30 | 0.76 | −2.08 | 1.49 | |
| Risperidone | 69.64 | −1.92 | 0.75 | −3.70 | −0.14 | * |
| Months 1, 3, and 6 (n = 2492 observations from 978 patients) | ||||||
| Perphenazine | 69.25 | |||||
| Olanzapine | 67.14 | 2.11 | 0.90 | −0.03 | 4.25 | |
| Quetiapine | 69.78 | −0.53 | 0.92 | −2.71 | 1.64 | |
| Risperidone | 71.80 | −2.55 | 0.92 | 4.72 | −0.39 | * |
| Months 9 and 12 (n = 1273 observations from 677 patients) | ||||||
| Perphenazine | 64.84 | |||||
| Olanzapine | 63.97 | 0.87 | 1.35 | −2.32 | 4.07 | |
| Quetiapine | 65.89 | −1.05 | 1.42 | −4.40 | 2.30 | |
| Risperidone | 67.10 | −2.26 | 1.41 | −5.57 | 1.06 | |
| Months 15 and 18 (n = 1054 observations from 578 patients) | ||||||
| Perphenazine | 63.52 | |||||
| Olanzapine | 61.12 | 2.40 | 1.52 | −1.19 | 5.98 | |
| Quetiapine | 63.25 | 0.27 | 1.61 | −3.53 | 4.08 | |
| Risperidone | 63.62 | −0.10 | 1.62 | −3.92 | 3.71 | |
| Phase 1 only | ||||||
| All data during 18 mos (n = 4453 observations from 1047 patients) | ||||||
| Perphenazine | 66.34 | |||||
| Olanzapine | 65.25 | 1.09 | 0.75 | −0.67 | 2.85 | |
| Quetiapine | 67.89 | −1.55 | 0.79 | −3.41 | 0.31 | |
| Risperidone | 68.52 | −2.18 | 0.77 | −4.00 | −0.36 | |
| Months 1, 3, and 6 (n = 2122 observations from 973 patients) | ||||||
| Perphenazine | 69.01 | |||||
| Olanzapine | 66.69 | 2.32 | 0.96 | 0.05 | 4.58 | * |
| Quetiapine | 69.38 | −0.37 | 0.98 | −2.69 | 1.95 | |
| Risperidone | 71.46 | −2.45 | 0.98 | −4.75 | −0.14 | * |
| Months 9 and 12 (n = 731 observations from 401 patients) | ||||||
| Perphenazine | 61.28 | |||||
| Olanzapine | 62.21 | −0.93 | 1.69 | −5.43 | 2.68 | |
| Quetiapine | 64.24 | −2.96 | 1.83 | −7.86 | 0.99 | |
| Risperidone | 65.11 | −3.83 | 1.78 | −8.36 | −0.23 | * |
| Months 15 and 18 (n = 553 observations from 307 patients) | ||||||
| Perphenazine | 60.29 | |||||
| Olanzapine | 59.67 | 0.62 | 1.88 | −3.70 | 5.46 | |
| Quetiapine | 64.00 | −3.71 | 2.15 | −9.11 | 1.38 | |
| Risperidone | 60.23 | 0.06 | 2.04 | −4.55 | 5.40 | |
a
Patients with tardive dyskinesia at baseline were excluded for all groups in this randomization. Because of missing data, two cases were excluded from these analyses.
b
Significance of paired differences between perphenazine and each SGA (*p < 0.017 due to Bonferroni’s correction for three comparisons).
LS indicates least squares.